Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis (NCT04458688)
Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis: a Novel, Advanced Multimodal MRI and Optical Coherence Tomography-Angiography (OCTA) Study
🩺 Plain-English Summary (8th-Grade Level)
The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..
Who can join: Review the eligibility criteria below.
Location: Wayne State University — Detroit, Michigan
Age range: 18 Years to 60 Years
🧪 Interventions in This Study
- Observation of Ocrelizumab as Treatment in RRMS Patients (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Wayne State University — Detroit, Michigan
📞 Contact the Study Coordinator
Phone: (313) 966-0473
Email: zahidlatif@wayne.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Sclerosis, Relapsing-Remitting
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS — Aurora, Colorado
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial — Birmingham, Alabama
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis — La Jolla, California
- Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis — Altamonte Springs, Florida
- A Post-Authorization, Long-term Study of Ozanimod Real-world Safety — Bethesda, Maryland
- Efficacy of Diet on Quality of Life in Multiple Sclerosis — Iowa City, Iowa
Explore by condition: All Multiple Sclerosis, Relapsing-Remitting clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.